Liabilities / Assets
67th percentile
Higher debt load relative to assets than 67% of similar nonprofits.
EIN 75-2727375 • 501(c)3 • Dallas, TX
Profile
To explore investigational vaccine, gene and cellular therapies with the goal of expanding treatment options for cancer patients.
Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.
Liabilities / Assets
67th percentile
Higher debt load relative to assets than 67% of similar nonprofits.
Liabilities / Revenue
66th percentile
Higher debt load relative to revenue than 66% of similar nonprofits.
Net Margin
71st percentile
Higher net margin than 71% of similar nonprofits.
Top Officer Pay
94th percentile
Higher top officer pay than 94% of similar nonprofits.
Top officer pay equals 3.6% of source-year revenue.
Asset Growth
75th percentile
Faster asset growth than 75% of similar nonprofits.
Revenue Growth
70th percentile
Faster revenue growth than 70% of similar nonprofits.
Assets
Up$24,324,731
Up $3,046,395 (+14%) from 2023
Liabilities
Down$8,744,793
Down $449,483 (-4.9%) from 2023
Net Assets
Up$15,579,938
Up $3,495,878 (+29%) from 2023
Revenue
Up$20,603,348
Up $3,326,564 (+19%) from 2023
Expenses
Up$17,107,470
Up $1,903,029 (+13%) from 2023
Net Income
Up$3,495,878
Up $1,423,535 (+69%) from 2023
Most recent year
2024 • Form 990Detailed filing. Detailed filing data is available for this year.
Similar nonprofits based on the same Siviq industry and scale cohort. 501(c)3 • $10M-$25M nonprofits
Utica, NY
View Organization501(c)3
Revenue vs current organization
18% higherAssets vs current organization
90% lowerPhiladelphia, PA
View Organization501(c)3
Revenue vs current organization
16% higherAssets vs current organization
About the sameLittle Rock, AR
View Organization501(c)3
Revenue vs current organization
25% lowerAssets vs current organization
About the sameBothell, WA
View Organization501(c)3
Revenue vs current organization
37% lowerAssets vs current organization
About the same